Health
Astra to Split Drug Production Along China-US Fault Lines
- CEO Soriot envisions parallel supply chains for medicines
- Drug invention, development, manufacturing will be distinct
This article is for subscribers only.
AstraZeneca Plc is fleshing out plans for a manufacturing network that will independently supply drugs to major markets as the US pushes to reduce the pharma industry’s reliance on China.
The UK drugmaker will make the same medicine at different facilities to serve various markets separately, Chief Executive Officer Pascal Soriot said in an interview from the sidelines of the Bo’ao Forum for Asia.